Described is the preparation of novel fentanyl haptens of Formula (1) through (6) and their use in the preparation of effective fentanyl vaccines.

The present invention relates to conjugates comprising B- and T-cell epitopes, vaccine compositions comprising said conjugates, their use in the prevention and treatment of cancer, such as prostate cancer, as well as kits comprising the conjugates and/or vaccine compositions. Also claimed are particular T-cell epitope-containing antigenic peptides, and nucleic acids encoding them and constructs and vectors comprising such nucleic acids.

The present invention is directed towards conjugates comprising fragments of the capsular polysaccharide of Type III Group B Streptococcus (GBS). Suitable fragments may be produced synthetically or by depolymerisation of native polysaccharide.

Compositions and methods are described for inducing an immune response against extra-intestinal pathogenic Escherichia coli (ExPEC) to thereby provide immune protection against diseases associated with ExPEC. In particular, compositions and methods are described for using conjugates of E. coli polysaccharide antigens O25B, O1A, O2, and O6A covalently bound to a detoxified exotoxin A of Pseudomonas aeruginosa (EPA) carrier protein as vaccines for the prevention of invasive ExPEC disease caused by ExPEC serotypes O1A, O2, O6A and O25B.

The present invention relates to a melittin-anticancer drug conjugate in which melittin and an anticancer drug are conjugated, and to a method of preparing a melittin-anticancer drug conjugate by connecting melittin and an anticancer drug. A conjugate of the present invention is an anticancer material for targeting M2-type tumor-associated macrophages (TAM) and exhibits an excellent effect of selectively selecting M2-type tumor-associated macrophages (TAM), and thus may be used for a use of drug delivery for targeting M2-type tumor-associated macrophages.

This invention is directed to immunogenic composition, conjugates, virus-like particles (VLP) compositions, vaccines and methods directed to the treatment and/or prevent of infection by Human Papillomavirus.

The present invention concerns antibody-conjugates comprising an anti-CEACAM5-antibody for use for treating cancer in combination with folinic acid, 5-fluoro-uracil and irinotecan (FOLFIRI). The invention further relates to pharmaceutical compositions and kit-of-parts comprising an anti-CEACAM5-antibody in combination with folinic acid, 5-fluoro-uracil and irinotecan (FOLFIRI) for use for treating cancer.

The present invention relates to a synthetic saccharide of general formula (I) that is related to Klebsiella pneumoniae serotype O1, O2, O2ac, and O8 O-polysaccharide and carbapenem-resistant Klebsiella pneumoniae ST258 O-polysaccharide and conjugate thereof. Said synthetic saccharide, said conjugate and pharmaceutical composition containing said synthetic saccharide or said conjugate are useful for prevention and/or treatment of diseases associated with Klebsiella pneumoniae. Furthermore, the synthetic saccharide of general formula (I) is useful as marker in immunological assays for detection of antibodies against Klebsiella pneumoniae bacteria.

The present invention provides isolated monoclonal antibodies which bind to the MUC1 SEA domain. The invention also concerns the use of these antibodies in therapeutic and diagnostic methods.

The present disclosure relates generally to methods of preparing glycoconjugates containing a saccharide conjugated to a carrier protein by use of stable nitroxyl radical related agent/oxidant as an oxidizing agent, to immunogenic compositions comprising such glycoconjugates, and to methods for the use of such glycoconjugates and immunogenic compositions.